MTOR and oral mucositis: As mentioned, mTOR inhibitor–associated stomatitis9, 10 has become the preferred descriptor over oral mucositis in order to differentiate the oral mucosal lesions associated with targeted therapies from the oral mucositis caused by conventional cancer therapy 7, 19.